Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entacapone Combined With Bevacizumab in Glioblastoma at First Recurrence
NCT07831187Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of entacapone in glioblastoma (GBM) (3 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Dose-Limiting Toxicities at 28 days and Progression-Free Survival up to 30 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
entacapone
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07831187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831187.